Annovis_Corp_Image.png
Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights
October 15, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
July 20, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
July 07, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
June 16, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
June 02, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68  Parkinson’s and Alzheimer’s Patients
April 30, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies
April 23, 2020 07:00 ET | Annovis Bio Inc.
BERWYN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other...
Annovis_Corp_Image.png
Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
February 27, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s (AD) , Parkinson’s (PD) and other...
Annovis_Corp_Image.png
Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases
February 20, 2020 07:00 ET | Annovis Bio Inc.
BERWYN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative...
Annovis_Corp_Image.png
Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease
February 13, 2020 11:40 ET | Annovis Bio Inc.
BERWYN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative...